Cereno Scientific’s drug candidate CS1 has obtained strengthened patent protection through its third patent family
Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS1’s third patent family has obtained issued patents in Australia and South Korea. This strengthens and broadens the intellectual property rights (IPR) for Cereno’s Phase II drug candidate CS1, which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).
“This is the fourth announcement in a short period of time that is related to the expansion of patent protection for assets in our portfolio. I am pleased to see the progress we are making with our intellectual property rights (IPR) as it is important for the future commercial potential of the company as well as our clinical and preclinical drug candidates,” said Sten R. Sörensen, CEO at Cereno.
CS1’s third patent family is titled “Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof.” The Australian patent has been assigned number 2017246697 and the South Korean patent has been issued under number 2438395. The patents will be valid through 2037, with the possibility of patent extension of up to five years. The third patent family has previously been granted in Japan, Russia, and the US.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.